Equities Analysts Issue Forecasts for Moderna Q3 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Equities research analysts at William Blair lowered their Q3 2025 earnings per share estimates for Moderna in a report released on Thursday, October 23rd. William Blair analyst M. Minter now anticipates that the company will earn ($2.54) per share for the quarter, down from their prior estimate of ($2.26). The consensus estimate for Moderna’s current full-year earnings is ($9.61) per share. William Blair also issued estimates for Moderna’s Q4 2025 earnings at ($3.34) EPS, FY2025 earnings at ($10.53) EPS, Q1 2026 earnings at ($2.99) EPS, Q2 2026 earnings at ($2.82) EPS, Q3 2026 earnings at ($1.93) EPS, Q4 2026 earnings at ($1.56) EPS and FY2026 earnings at ($9.30) EPS.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts’ consensus estimates of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm’s revenue was down 41.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS.

Several other equities research analysts have also recently weighed in on MRNA. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Monday, October 20th. Cowen initiated coverage on Moderna in a research note on Sunday, July 13th. They issued a “hold” rating for the company. Citigroup decreased their price target on Moderna from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Thursday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moderna in a report on Saturday. Finally, Barclays reduced their target price on Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a report on Monday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, twelve have given a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $36.86.

Moderna Stock Up 1.9%

Shares of Moderna stock opened at $26.74 on Monday. The stock has a market capitalization of $10.44 billion, a P/E ratio of -3.55 and a beta of 2.01. The stock has a 50 day moving average price of $25.94 and a two-hundred day moving average price of $27.15. Moderna has a 12-month low of $23.15 and a 12-month high of $57.69.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. S Bank Fund Management Ltd acquired a new position in shares of Moderna during the 1st quarter worth approximately $25,000. Rothschild Investment LLC boosted its stake in Moderna by 94.1% in the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after purchasing an additional 446 shares during the period. TD Private Client Wealth LLC boosted its stake in Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after purchasing an additional 743 shares during the period. Atlantic Union Bankshares Corp bought a new stake in shares of Moderna during the 2nd quarter valued at $26,000. Finally, SVB Wealth LLC bought a new stake in shares of Moderna during the 1st quarter valued at $28,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.